Literature DB >> 22151786

Reprogramming of gastrointestinal cancer cells.

DyahLaksmi Dewi1, Hideshi Ishii, Naotsugu Haraguchi, Shimpei Nishikawa, Yoshihiro Kano, Takahito Fukusumi, Katsuya Ohta, Susumu Miyazaki, Miyuki Ozaki, Daisuke Sakai, Taroh Satoh, Hiroaki Nagano, Yuichiro Doki, Masaki Mori.   

Abstract

Cell reprogramming reverts cells to multipotent, preprogrammed states by re-establishing epigenetic markers. It can also induce considerable malignant phenotype modification. Because key events in cancer relapse and metastasis, including epithelial-mesenchymal transition phenotypes, are regulated primarily by reversible and transient epigenetic modifications rather than the accumulation of irreversible and stable genetic abnormalities, studying dynamic mechanisms regulating these biological processes is important. Transcription factors for induced pluripotent stem cells and non-coding microRNAs allow pluripotent phenotype induction. We present the current knowledge of the possible applications of cell reprogramming in reducing aggressive phenotype expression, which can induce tumor cell hibernation and maintain appropriate phenotypes, thereby minimizing relapse and metastasis after surgical resection of gastrointestinal cancer.
© 2011 Japanese Cancer Association.

Entities:  

Mesh:

Year:  2012        PMID: 22151786      PMCID: PMC7713613          DOI: 10.1111/j.1349-7006.2011.02184.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  89 in total

Review 1.  Stem cells: a new lease on life.

Authors:  E Fuchs; J A Segre
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Epigenetic pre-patterning and dynamics during initial stages of mammalian preimplantation development.

Authors:  Theodore P Rasmussen; Gareth N Corry
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

3.  Two supporting factors greatly improve the efficiency of human iPSC generation.

Authors:  Yang Zhao; Xiaolei Yin; Han Qin; Fangfang Zhu; Haisong Liu; Weifeng Yang; Qiang Zhang; Chengang Xiang; Pingping Hou; Zhihua Song; Yanxia Liu; Jun Yong; Pengbo Zhang; Jun Cai; Meng Liu; Honggang Li; Yanqin Li; Xiuxia Qu; Kai Cui; Weiqi Zhang; Tingting Xiang; Yetao Wu; Yiding Zhao; Chun Liu; Chen Yu; Kehu Yuan; Jinning Lou; Mingxiao Ding; Hongkui Deng
Journal:  Cell Stem Cell       Date:  2008-11-06       Impact factor: 24.633

4.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.

Authors:  D Bonnet; J E Dick
Journal:  Nat Med       Date:  1997-07       Impact factor: 53.440

5.  Immortalization eliminates a roadblock during cellular reprogramming into iPS cells.

Authors:  Jochen Utikal; Jose M Polo; Matthias Stadtfeld; Nimet Maherali; Warakorn Kulalert; Ryan M Walsh; Adam Khalil; James G Rheinwald; Konrad Hochedlinger
Journal:  Nature       Date:  2009-08-09       Impact factor: 49.962

6.  Induced pluripotent stem cell lines derived from human somatic cells.

Authors:  Junying Yu; Maxim A Vodyanik; Kim Smuga-Otto; Jessica Antosiewicz-Bourget; Jennifer L Frane; Shulan Tian; Jeff Nie; Gudrun A Jonsdottir; Victor Ruotti; Ron Stewart; Igor I Slukvin; James A Thomson
Journal:  Science       Date:  2007-11-20       Impact factor: 47.728

7.  Generation of germline-competent induced pluripotent stem cells.

Authors:  Keisuke Okita; Tomoko Ichisaka; Shinya Yamanaka
Journal:  Nature       Date:  2007-06-06       Impact factor: 49.962

8.  Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells.

Authors:  Ning Sun; Nicholas J Panetta; Deepak M Gupta; Kitchener D Wilson; Andrew Lee; Fangjun Jia; Shijun Hu; Athena M Cherry; Robert C Robbins; Michael T Longaker; Joseph C Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-08       Impact factor: 11.205

9.  Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome.

Authors:  Noemi Fusaki; Hiroshi Ban; Akiyo Nishiyama; Koichi Saeki; Mamoru Hasegawa
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2009       Impact factor: 3.493

10.  piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells.

Authors:  Knut Woltjen; Iacovos P Michael; Paria Mohseni; Ridham Desai; Maria Mileikovsky; Riikka Hämäläinen; Rebecca Cowling; Wei Wang; Pentao Liu; Marina Gertsenstein; Keisuke Kaji; Hoon-Ki Sung; Andras Nagy
Journal:  Nature       Date:  2009-03-01       Impact factor: 49.962

View more
  5 in total

1.  A highly optimized protocol for reprogramming cancer cells to pluripotency using nonviral plasmid vectors.

Authors:  Hongzhi Zhao; Timothy J Davies; Jiaolin Ning; Yanxu Chang; Patty Sachamitr; Susanne Sattler; Paul J Fairchild; Fang-Ping Huang
Journal:  Cell Reprogram       Date:  2014-12-30       Impact factor: 1.987

2.  Expression and Functional Role of Reprogramming-Related Long Noncoding RNA (lincRNA-ROR) in Glioma.

Authors:  Shiyu Feng; Jie Yao; Yang Chen; Peiliang Geng; Haibo Zhang; Xiaodong Ma; Jing Zhao; Xinguang Yu
Journal:  J Mol Neurosci       Date:  2015-02-05       Impact factor: 3.444

3.  Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Authors:  Begoña Martin-Castillo; Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Silvia Cufí; José Manuel Moreno; Bruna Corominas-Faja; Ander Urruticoechea; Ángel G Martín; Eugeni López-Bonet; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

Review 4.  Advances and Challenges on Cancer Cells Reprogramming Using Induced Pluripotent Stem Cells Technologies.

Authors:  Diana Aparecida Dias Câmara; Lisley Inata Mambelli; Allan Saj Porcacchia; Irina Kerkis
Journal:  J Cancer       Date:  2016-11-25       Impact factor: 4.207

5.  Immortalized murine fibroblast cell lines are refractory to reprogramming to pluripotent state.

Authors:  Elena V Skvortsova; Sergey A Sinenko; Alexey N Tomilin
Journal:  Oncotarget       Date:  2018-10-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.